Ajanta Pharma Ltd

ajantapharma.com

Ajanta Pharma Limited (APL) is a pharmaceutical company headquartered in Mumbai, India. It has strong presence in Branded Generic business in India & Emerging markets; and Generic business in USA.In India, company operates in selected therapeutic areas of Cardiology, Dermatology, Ophthalmology and Pain management. Its brands in each of sub-therapeutic areas or molecules hold leadership positions.In Emerging Markets, company has presences in Africa, Asia, Middle East, and CIS on broader therapeutic segments such as anti-malarial, gastro, antibiotics, cardiology, dermatology, pain management, etc.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

ZYNEX SUBMITS FDA APPLICATION FOR ITS NEXT GENERATION FLUID AND BLOOD VOLUME MONITOR

Zynex | January 04, 2022

news image

Zynex, Inc. an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced that it has submitted a 510(k) application to the U.S. Food and Drug Administration for the CM-1600, its next generation fluid monitoring system. "I am thrilled to announce that we have submitted a 510(k) premarket notification to the FDA for our CM...

Read More

HITGEN AND MORPHIC THERAPEUTIC EXTEND DRUG DISCOVERY RESEARCH COLLABORATION TO IDENTIFY SMALL MOLECULE LEADS AGAINST TARGETS

HitGen Inc., Morphic Therapeutic | July 06, 2020

news image

HitGen Inc. announced today that HitGen and Morphic Therapeutic have extended their drug discovery research collaboration to identify small molecule leads against targets specified by Morphic. HitGen’s industry-leading DNA-encoded library (DEL) technology platform includes over 400 billion encoded syntheses of small molecules with drug-like properties, synthesized on chemically-diverse scaffolds. The collaboration is an extension of a previous agreement which identified active lead compoun...

Read More

Business Insights, PHARMACY MARKET

MASSIVE BIO AND NEOGENOMICS ANNOUNCE COLLABORATION TO ACCELERATE ONCOLOGY DRUG DISCOVERY AND IMPROVE PATIENT CARE

Businesswire | March 27, 2023

news image

Massive Bio, Inc., a private AI-enabled oncology startup that provides virtual and in-person concierge services for cancer patients, and NeoGenomics, Inc. a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced a collaboration with the goal of accelerating the development of new cancer therapies and ultimately improving the lives of millions of cancer patients around the world. NeoGenomics will identify patients in real ...

Read More

Pharmacy Market

AVACTA ANNOUNCES FDA APPROVAL OF ITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR AVA6000

Avacta | November 29, 2021

news image

Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AVA6000. This will allow the Group to expand its Phase I clinical trial, ALS-6000-101, into clinical trial sites in the United States. AVA6000 is a novel f...

Read More
news image

Pharma Tech

ZYNEX SUBMITS FDA APPLICATION FOR ITS NEXT GENERATION FLUID AND BLOOD VOLUME MONITOR

Zynex | January 04, 2022

Zynex, Inc. an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced that it has submitted a 510(k) application to the U.S. Food and Drug Administration for the CM-1600, its next generation fluid monitoring system. "I am thrilled to announce that we have submitted a 510(k) premarket notification to the FDA for our CM...

Read More
news image

HITGEN AND MORPHIC THERAPEUTIC EXTEND DRUG DISCOVERY RESEARCH COLLABORATION TO IDENTIFY SMALL MOLECULE LEADS AGAINST TARGETS

HitGen Inc., Morphic Therapeutic | July 06, 2020

HitGen Inc. announced today that HitGen and Morphic Therapeutic have extended their drug discovery research collaboration to identify small molecule leads against targets specified by Morphic. HitGen’s industry-leading DNA-encoded library (DEL) technology platform includes over 400 billion encoded syntheses of small molecules with drug-like properties, synthesized on chemically-diverse scaffolds. The collaboration is an extension of a previous agreement which identified active lead compoun...

Read More
news image

Business Insights, PHARMACY MARKET

MASSIVE BIO AND NEOGENOMICS ANNOUNCE COLLABORATION TO ACCELERATE ONCOLOGY DRUG DISCOVERY AND IMPROVE PATIENT CARE

Businesswire | March 27, 2023

Massive Bio, Inc., a private AI-enabled oncology startup that provides virtual and in-person concierge services for cancer patients, and NeoGenomics, Inc. a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced a collaboration with the goal of accelerating the development of new cancer therapies and ultimately improving the lives of millions of cancer patients around the world. NeoGenomics will identify patients in real ...

Read More
news image

Pharmacy Market

AVACTA ANNOUNCES FDA APPROVAL OF ITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR AVA6000

Avacta | November 29, 2021

Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AVA6000. This will allow the Group to expand its Phase I clinical trial, ALS-6000-101, into clinical trial sites in the United States. AVA6000 is a novel f...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us